Hikma Builds On US Biosimilar Ambitions With Deal For Richter’s Denosumab
License For Prolia And Xgeva Rivals Follows Ustekinumab Deal With Bio-Thera
• By David Wallace
The next piece has fallen into place for Hikma’s US biosimilars business • Source: Alamy 
